logo

For the Inventor, By the Inventor

Holzkirchen, Germany

Hexal Ag


USPTO Granted Patents = 47

% Expired Patents = 42.6



Forward Citations = 553

Loading Chart...
Loading Chart...

59 inventors (with patents filed for the assignee):

goldMedal Karin Klokkers (16 out of 19 patents)

silverMedal Wilfried Fischer (14 out of 18 patents)

bronzeMedal Ralf Kibele (5 out of 12 patents)

4.  Andreas Krekeler (5 out of 6 patents)

5.  Anna Sendl-Lang (5 out of 5 patents)

6.  Daniel Bracher (4 out of 4 patents)

7.  Brigitte Freudensprung (3 out of 3 patents)

8.  Dimitri Neumann (2 out of 2 patents)

9.  Michael Sedlmayr (2 out of 3 patents)

10.  Jörg Nink (2 out of 2 patents)

11.  Thomas Kohr (2 out of 2 patents)

12.  Peter Skufca (2 out of 4 patents)

13.  Theresa Taeubrich (2 out of 2 patents)

14.  Patrick Rother (2 out of 2 patents)

15.  Cornelia Beier (2 out of 2 patents)


Core Competencies:
Transdermal Systems
Sustained-Release Tablets
Pharmaceutical Composition
Taste-Masking Agents
Alogliptin Formulation
Crystalline Brexpiprazole
Orodispersible Film
Pharmaceutical Antacid
Biopharmaceutical Drug
Active Ingredients
Migraine Treatment
Controlled-Release Preparations

47 patents:

1. 11123300 - Immediate release tablet of a benzothiophene compound (2021-09-21),
2. 11072605 - Crystalline brexpiprazole (2021-07-27),
3. 11021530 - Antibody preparation (2021-06-01),
4. 10732162 - Method and device for determining the disintegration time of film-shaped pharmaceutical dosage forms (2020-08-04),
5. 10668073 - Pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof (2020-06-02),
6. 10548848 - Alogliptin formulation (2020-02-04),
7. 10501450 - Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations (2019-12-10),
8. 10485799 - Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix (2019-11-26),
9. 10335443 - Orodispersible film (2019-07-02),
10. 9895497 - Method for reducing leachables and extractables in syringes (2018-02-20),
11. 9844515 - Transdermal therapeutic system comprising buprenorphine (2017-12-19),
12. 9789112 - Oral pharmaceutical film formulation for bitter tasting drugs (2017-10-17),
13. 9717707 - Pharmaceutical statin composition (2017-08-01),
14. 9592296 - Pharmaceutical composition for oral administration with a statin (2017-03-14),
15. 9480743 - Pharmaceutical formulation comprising a biopharmaceutical drug (2016-11-01),
Hexal AG, headquartered in Holzkirchen, Germany, is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of innovative drug formulations. The company focuses on advanced technologies such as benzothiophene compounds and crystalline brexpiprazole, alongside expertise in antibody preparation and orodispersible films. Hexal AG is dedicated to creating effective pharmaceutical compositions, including sustained-release formulations and transdermal therapeutic systems, aimed at enhancing patient compliance and therapeutic outcomes.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Hexal Ag
47 Patents

#1 in Holzkirchen

#1,123 in Germany

#14,803 in the World

Holzkirchen, DE
Holzkirchen, Germany

Hexal Ag

Forward Citations = 553

59 inventors:

goldMedal Karin Klokkers (16 out of 19 patents)

silverMedal Wilfried Fischer (14 out of 18 patents)

bronzeMedal Ralf Kibele (5 out of 12 patents)

4.  Andreas Krekeler (5 out of 6 patents)

5.  Anna Sendl-Lang (5 out of 5 patents)

Please report any incorrect information to [email protected]
Loading…